Previous close | 131.06 |
Open | 131.18 |
Bid | 131.25 x 800 |
Ask | 133.32 x 900 |
Day's range | 131.18 - 133.41 |
52-week range | 119.59 - 148.62 |
Volume | |
Avg. volume | 1,045,526 |
Market cap | 14.736B |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | 17.51 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.00 (2.29%) |
Ex-dividend date | 05 Apr 2024 |
1y target est | N/A |
A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physicians establish that Alzheimer's disease (AD) is likely not the cause of patients' mild cognitive impairment, finds a new study published in Frontiers in Neurology by researchers from Quest Diagnostics (NYSE: DGX), the University of Florida and Mount Sinai Medical Center in Miami Beach.
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the Barclays 26th Annual Global Healthcare Conference in Miami on Wednesday, March 13, 2024, at 10:15 a.m. Eastern Time.